Risk factors
Editas Medicine (EDIT) risk factors
Item 1A of every Editas Medicine, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks6 new10 dropped15 reworded
Editas Medicine highlights preclinical reliance on EDIT-401, ongoing net losses totaling $1.6 billion, and risks from U.S. government shutdowns impacting FDA reviews.
Filed Mar 09, 2026 - FY2024 10-K risk factors68 risks
Editas faces significant operating losses, an accumulated deficit of $1.47 billion, and requires substantial additional capital.
Filed Mar 05, 2025